Recode Therapeutics Announces Closing Of Extension To Series B Financing
PRIVATESep 19, 2023
Round Type
Series B
Menlo ParkBiotechnologyHealthcareHealth Care
Investors
Bioluminescence Ventures
Description
ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
Who to call at ReCode Therapeutics, and when
A new round usually means ReCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day ReCode Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at ReCode Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
ReCode Therapeutics
Location
Menlo Park, California, United States
About
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ReCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Menlo ParkBiotechnologyHealthcareHealth Care